Market Research Report
Europe Pneumonia Vaccines Market (2019-2025)
|Published by||KBV Research||Product code||888288|
|Published||Content info||102 Pages
Delivery time: 1-2 business days
|Europe Pneumonia Vaccines Market (2019-2025)|
|Published: June 30, 2019||Content info: 102 Pages||
The Europe Pneumonia Vaccines Market would witness market growth of 4.5% CAGR during the forecast period (2019-2025).
Pneumococcal diseases are most common in younger children; however, adults and the elderly population are also prone to pneumococcal contaminations that lead to death as well. Pneumonia vaccines are primarily given to the children less than 2 years and to the adults of 65 years and older. These vaccines help to provide immunization against 13 types of pneumococcal bacteria that cause infection in the lungs. Increasing government support in creating awareness regarding pneumonia immunization programs, rising prevalence of pneumococcal contaminations within the population, and introduction of novel pneumococcal vaccines are some of the major factors driving the growth of the global pneumonia vaccine market. However, longer timelines required for the production of pneumococcal vaccines and higher costs associated with the development of the vaccines are hindering the growth of the market.
Based on Vaccine Type, the market is segmented into Pneumococcal conjugate vaccine (PCV) and Pneumococcal polysaccharide vaccine (PPSV/PPV). Based on Product Type, the market is segmented into Prevnar 13, Synflorix and Pneumovax23. According to sector, the market is segmented into Public sector and Private sector. Based on Distribution Channel, the market is further segmented into Distribution partner companies, Non-governmental Organizations (NGO) and Government Authorities. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glaxosmithkline Plc. (GSK), LG Corporation, Panacea Biotec Limited, Pfizer, Inc., Pnuvax Incorporated, Poonawalla Investments & Industries Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., SK Holdings Co., Ltd., Walvax Biotechnology Co., Ltd. And MERCK & CO., Inc.